Haemonetics Corp. (NYSE:HAE) announced Friday it has acquired Vivasure Medical Limited, a Galway-based pioneer in vessel closure technology, in a move that significantly broadens its reach into the $2.5 billion global vascular closure market.
The transaction includes an upfront cash payment of €100 million ($109 million), with an additional €85 million ($93 million) tied to future sales milestones and clinical goals.
Because Haemonetics was a prior investor in Vivasure, the net upfront cash outlay is approximately €52 million.
The centerpiece of the acquisition is the PerQseal® Elite, a percutaneous large-bore vessel closure system designed to seal arterial and venous access sites following complex heart procedures like TAVR (transcatheter aortic valve replacement).
Unlike traditional methods that use permanent metal clips or sutures, the PerQseal system uses a fully bioabsorbable patch that is placed from inside the vessel. This allows the artery to heal naturally, with the patch dissolving completely within six months.
Clinical data from the ELITE study supported the acquisition, reporting a 0% major complication rate at 30 days and a median "immediate" time to hemostasis (bleeding cessation).
Vivasure submitted its Premarket Approval (PMA) application to the U.S. FDA in late 2025, and the device already holds a CE Mark for sale in Europe.
Haemonetics financed the deal using cash on hand.
The company expects the acquisition to be slightly dilutive to adjusted earnings in the short term due to integration and R&D costs, but anticipates it will become a significant growth driver by 2027 as U.S. commercialization ramps up.